Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

Andreas Reif, A. Elif Anıl Yağcıoğlu, Istvan Bitter, Jozefien Buyze, Richard Frey, Dong Jing Fu, Yordan Godinov, Lars Haggström, Yerkebulan Kambarov, René E. Nielsen, Albino J. Oliveira-Maia, Christian von Holt, Allan H. Young, Wiesław J. Cubała

Eur Neuropsychopharmacol • June 5, 2026 • DOI: 10.1016/j.euroneuro.2026.112885 • via PubMed